# BAX 802 in CHA With Inhibitors

> **NCT02895945** · PHASE3 · TERMINATED · sponsor: **Baxalta now part of Shire** · enrollment: 8 (actual)

## Conditions studied

- Hemophilia A

## Interventions

- **BIOLOGICAL:** Antihemophilic Factor (Recombinant), Porcine Sequence (BAX 802)

## Key facts

- **NCT ID:** NCT02895945
- **Lead sponsor:** Baxalta now part of Shire
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-12-22
- **Primary completion:** 2021-01-22
- **Final completion:** 2021-01-22
- **Target enrollment:** 8 (ACTUAL)
- **Why stopped:** Takeda has determined that the benefit/risk profile does not support continuation of the surgery Study for this specific Congenital Hemophilia A with Inhibitors patient population.
- **Last updated:** 2021-10-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02895945

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02895945, "BAX 802 in CHA With Inhibitors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02895945. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*